ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna Szydzik; Dan E. Lind; Badrul Arefin; Yeshwant Kurhe; Ganesh Umapathy; Joachim Tetteh Siaw; Arne Claeys; Jonatan L. Gabre; Jimmy Van den Eynden; Bengt Hallberg; Ruth H. Palmer

doi:10.1038/s41467-021-27057-2

Nature Communications (Nov 2021)

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna Szydzik,
Dan E. Lind,
Badrul Arefin,
Yeshwant Kurhe,
Ganesh Umapathy,
Joachim Tetteh Siaw,
Arne Claeys,
Jonatan L. Gabre,
Jimmy Van den Eynden,
Bengt Hallberg,
Ruth H. Palmer

Affiliations

Joanna Szydzik: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Dan E. Lind: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Badrul Arefin: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Yeshwant Kurhe: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Ganesh Umapathy: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Joachim Tetteh Siaw: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Arne Claeys: Department of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University
Jonatan L. Gabre: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Jimmy Van den Eynden: Department of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University
Bengt Hallberg: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg
Ruth H. Palmer: Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg

DOI: https://doi.org/10.1038/s41467-021-27057-2
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 18

Abstract

Read online

Effective therapeutic options are still needed in neuroblastoma treatment. Here, the authors, through a comprehensive proteomics analysis, identify ATR as a potential therapeutic target of neuroblastoma and demonstrate the efficacy of the ATR inhibitor BAY1895344 in combination with the ALK tyrosine kinase inhibitor lorlatinib.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal